Skip to content

Group Therapy for Depressed Dementia Caregivers

Group Therapy for Depressed Caregivers of Alzheimer's Disorder and Related Dementias

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03092050
Enrollment
46
Registered
2017-03-27
Start date
2017-03-01
Completion date
2019-06-30
Last updated
2022-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

Depression in family caregivers of relatives with Alzheimer's Disorder and related dementias is a serious public health problem. This is a randomized, controlled, single-blind pilot clinical trial of depressed caregivers, to determine the efficacy and mechanisms of group therapy for depressed dementia caregivers.

Detailed description

The trial was designed to measure clinical outcomes including depressive symptoms and other secondary outcomes of caregivers of persons living with dementia. It also included magnetic resonance imagery scanning at baseline (prior to study group) and post group to identify candidate mechanisms of effects. Notes related to outcome measurement. On 05.10.2017 (prior to participant enrollment), all secondary outcomes were approved by the UCSF IRB #16-20163. It was noted in the IRB that the primary outcome timepoint was to be obtained 4 weeks after the first group session. Due to magnetic resonance imaging scanning scheduling constraints, which occurred at the same time as the 4 weeks visit, the outcome could not be exactly four weeks post the first group session but was collected approximately at this time. On 05.10.2017 (prior to participant enrollment), three-month post group secondary outcomes were also approved.

Interventions

BEHAVIORALGuided Imagery and Mindfulness

This is a behavioral intervention using guided imagery and mindfulness techniques.

BEHAVIORALFacilitated Discussion

This is a behavioral intervention that involves discussion and group support.

Sponsors

National Institute on Aging (NIA)
CollaboratorNIH
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Participants were blinded to study hypotheses. Under UCSF IRB #16-20163, on 07.21.2016 (prior to participant enrollment), IRB approval was received for a single-blind study (participant blinding only) due to funding constraints.

Intervention model description

2 arm randomized controlled trial. During the conduct of the trial, the investigators noted that due to staffing constraints, participant availability, and funding limitations, it would not be feasible to complete a crossover study. This was due to the fact that the investigators were unable to offer crossover group therapy visits at the same time as the initial group sessions. Rather, groups with new participants had to be prioritized and scheduled during the most accessible time slots. Times that the investigators could offer for crossover groups were often inaccessible to participants. Thus, the investigators determined that in the context of this pilot trial, it was not feasible to conduct a full crossover trial due to accessibility. The trial design was therefore updated to parallel (in accordance with the initial funding application).

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Endorse clinically relevant baseline depressive symptoms Primary caregiver for a relative with dementia

Exclusion criteria

Age \< 45 Meditation / guided imagery practice more than twice per week Ideas of harming relative with dementia Current violence towards relative with dementia Adult Protective Services report on file Primary psychiatric disorder other than unipolar major depression Cognitive impairment on the part of the caregiver (Mini Mental State Examination score less than 24) Unstable medical illness Planned surgery Active drug or alcohol abuse Inability to understand written and oral English.

Design outcomes

Primary

MeasureTime frameDescription
Depression symptomsapproximately 4 weeks post initial group sessionSelf reported depression symptoms (Quick Inventory of Depression Symptoms)

Secondary

MeasureTime frameDescription
Depression symptoms - clinician ratedapproximately 4 weeks post initial group session and approximately 3 months post initial group sessionHamilton Depression Rating Scale
Caregiver burdenapproximately 4 weeks post initial group session and approximately 3 months post initial group sessionCaregiver Burden Scale self rated questionnaire
Anxiety symptomsapproximately 4 weeks post initial group session and approximately 3 months post initial group sessionState Trait Anxiety Inventory - Trait
Mindfulnessapproximately 4 weeks post initial group session and approximately 3 months post initial group sessionFive Factor Mindfulness Questionnaire
Depression symptoms - moderate termapproximately 3 months post initial group sessionSelf reported depression symptoms
Well-Beingapproximately 4 weeks post initial group session and approximately 3 months post initial group sessionMental Health Continuum Short Form
Stressapproximately 4 weeks post initial group session and approximately 3 months post initial group sessionPerceived Stress Scale
Resilienceapproximately 4 weeks post initial group session and approximately 3 months post initial group sessionConnors Davidson Resilience Scale
Connectedness to Natureapproximately 4 weeks post initial group session and approximately 3 months post initial group sessionConnectedness to Nature Scale
Positive and Negative Affectapproximately 4 weeks post initial group session and approximately 3 months post initial group sessionPositive and Negative Affect Scale

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026